Severe Hypoglycemia Management
Severe Hypoglycemia Management: Suspected Hypoglycemia → Classify Hypoglycemia Level → Is Patient Conscious & Able to Swallow? → Oral Glucose Treatment ...
Interactive Decision Tree
Algorithm Steps
- ▶Start
Suspected Hypoglycemia
Patient with symptoms or confirmed low glucose
- ◆Decision
Classify Hypoglycemia Level
ADA Classification
- Level 1: Glucose 54-70 mg/dL (3.0-3.9 mmol/L) - Alert value
- Level 2: Glucose <54 mg/dL (<3.0 mmol/L) - Clinically significant
- Level 3: Severe - Altered mental status, requires assistance
- ◆Decision
Is Patient Conscious & Able to Swallow?
Assess mental status and ability to take PO
- ●Action
Oral Glucose Treatment
Rule of 15
- Give 15-20g fast-acting carbohydrate:
- - Glucose tablets (4 tabs = 16g)
- - 4 oz (120 mL) juice or regular soda
- - 1 tablespoon sugar or honey
- Recheck glucose in 15 minutes
- Repeat if still <70 mg/dL
- ●Action
Recheck Glucose in 15 Minutes
Assess response to treatment
- ◆Decision
Glucose >70 mg/dL & Symptoms Resolved?
Evaluate treatment response
- ●Action
Post-Treatment Care
Prevent recurrence
- Give substantial snack or meal if not eating soon
- Include protein and complex carbohydrates
- Review cause of hypoglycemia
- Adjust diabetes medications if needed
- Education on hypoglycemia prevention
- ●Action
Evaluate Underlying Cause
Identify precipitant to prevent recurrence
- Missed meal or reduced food intake
- Excess insulin or secretagogue dose
- Increased physical activity
- Alcohol consumption
- Renal or hepatic impairment
- Adrenal insufficiency (consider if recurrent)
- ✓Outcome
Hypoglycemia Resolved
Ensure follow-up and medication adjustment
- ⚠Warning
Hospital Admission
For refractory, sulfonylurea, or unclear cause
- ●Action
Repeat Treatment
Glucose still low
- Repeat glucose treatment
- Consider continuous D10W infusion
- Evaluate for sulfonylurea or long-acting insulin
- May need prolonged monitoring (12-24h)
- ⚠Warning
⚠️ Sulfonylurea Warning
Extended monitoring required
- Sulfonylurea-induced hypoglycemia may recur
- Monitor glucose every 1-2 hours for 12-24h
- Consider octreotide 50 mcg SubQ q6-8h
- Hospital admission often required
- ◆Decision
IV Access Available?
Determine route for treatment
- ●Action
IV Dextrose
Preferred if IV access present
- D50W: 25-50 mL (12.5-25g dextrose) IV push
- OR D10W: 100-250 mL if peripheral line
- Effect within 1-3 minutes
- May repeat in 15 minutes if needed
- Follow with D10W infusion if recurrent
- ●Action
Glucagon Administration
When IV access not available
- Intranasal: 3 mg single spray (preferred)
- IM/SubQ: 1 mg injection
- Auto-injector: Per device instructions
- Onset: 10-15 minutes
- Turn patient on side (aspiration risk)
- Less effective if glycogen depleted
Guideline Source
ADA Standards of Care in Diabetes - Glycemic Goals and Hypoglycemia 2025
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address neonatal hypoglycemia
- Sulfonylurea-induced hypoglycemia may require prolonged monitoring
- Does not cover insulinoma workup
- Requires access to glucagon preparations
Contraindicated Populations
Applicable Regions
EU: Check local glucagon formulation availability
US: Intranasal and auto-injector glucagon widely available
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Severe Hypoglycemia Management?
The Severe Hypoglycemia Management is a emergency clinical algorithm for Endocrinology. It provides a structured decision tree to guide clinical decision-making, based on ADA Standards of Care in Diabetes - Glycemic Goals and Hypoglycemia 2025.
What guideline is the Severe Hypoglycemia Management based on?
This algorithm is based on ADA Standards of Care in Diabetes - Glycemic Goals and Hypoglycemia 2025 (DOI: 10.2337/dc25-S006).
What are the limitations of the Severe Hypoglycemia Management?
Known limitations include: Does not address neonatal hypoglycemia; Sulfonylurea-induced hypoglycemia may require prolonged monitoring; Does not cover insulinoma workup; Requires access to glucagon preparations. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Severe Hypoglycemia Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free